-
FDA approval of oveporexton for narcolepsy allows clinicians to treat more than symptoms
When the US Food and Drug Administration approved the drug in August, oveporexton became the first agent to target the loss of orexin signaling that causes narcolepsy type 1.
Recent News
-
Matters of the right heart: Applying the 2025 ASE guidelines in PH practice
The latest guidelines from the American Society of Echocardiography emphasize three pillars of right-heart assessment: structure, function, and hemodynamics.
-
Keeping patients connected: Remote patient monitoring in sleep medicine
Implementing an RPM program is more than adopting new technology; it’s an opportunity for sleep medicine specialists to rethink how care is delivered outside the clinic.
-
Top reads from the CHEST journal portfolio – October 2026
Read new research from the journal portfolio on predicting clinical response to benralizumab using imaging, using machine learning to develop a risk score for ventilator-assisted pneumonia, and evaluating efficacy of omadacycline for MABC pulmonary disease.
-
Selpercatinib improves event-free survival in early-stage RET fusion-positive NSCLC
Alexander E. Drilon, MD, discusses the findings from the first randomized phase 3 trial to evaluate a RET kinase inhibitor as adjuvant therapy in RET fusion-positive lung cancer.
-
Intensive antiviral chemoprophylaxis in nursing homes reduces hospitalization
“The actionable message is not to aim for 100%; it is to reach the most residents in the first 48 hours,” said Viren Kaul, MD, FCCP.
-
Remote patient monitoring shows no benefit after serious infections, major trial finds
Researcher Sachin Yende, MD, MS, said the results challenge the assumption that remote monitoring alone improves postdischarge outcomes.
